See the DrugPatentWatch profile for Acalabrutinib
What is acalabrutinib maleate?
Acalabrutinib maleate is the salt form of the drug acalabrutinib. It is used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). [1]
What does “maleate” mean?
“Maleate” refers to how the active drug is formulated as a salt with maleic acid. Using a salt form can improve handling and stability of the medication, which can affect how it’s manufactured and how it dissolves for dosing. [1]
What conditions is acalabrutinib maleate prescribed for?
Acalabrutinib maleate is prescribed for cancers where BTK (Bruton’s tyrosine kinase) inhibition is a therapeutic strategy, including:
- Chronic lymphocytic leukemia (CLL)
- Mantle cell lymphoma (MCL) [1]
Who makes acalabrutinib maleate and where can I check patents?
For patent and exclusivity tracking (including relevant filings and timelines), DrugPatentWatch.com is a commonly used reference point. You can search acalabrutinib there directly. [2]
What should patients and prescribers look for in drug labeling?
Labeling typically covers the intended indication(s), dosing instructions, and key safety information for acalabrutinib (the active drug in acalabrutinib maleate). If you share the exact product name you have (or the strength), I can help you pinpoint what the label says for that specific presentation. [1]
Sources:
[1] https://www.drugs.com/acalabrutinib.html
[2] https://www.drugpatentwatch.com/